121 related articles for article (PubMed ID: 17212737)
1. Cyclosporin A can achieve immune tolerance in a patient with severe haemophilia B and refractory inhibitors.
Cross DC; Van Der Berg HM
Haemophilia; 2007 Jan; 13(1):111-4. PubMed ID: 17212737
[TBL] [Abstract][Full Text] [Related]
2. Successful second ITI with factor IX and combined immunosuppressive therapy. A patient with severe haemophilia B and recurrence of a factor IX inhibitor.
Holstein K; Schneppenheim R; Schrum J; Bokemeyer C; Langer F
Hamostaseologie; 2014; 34 Suppl 1():S5-8. PubMed ID: 25382771
[TBL] [Abstract][Full Text] [Related]
3. rFIXFc for Immune Tolerance Induction in a Severe Hemophilia B Patient with an Inhibitor and Prior History of ITI Related Nephrotic Syndrome.
Malec L; Abshire T; Jobe S; White G
Haemophilia; 2018 Jul; 24(4):e294-e296. PubMed ID: 30024646
[No Abstract] [Full Text] [Related]
4. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
[TBL] [Abstract][Full Text] [Related]
5. Successful induction of immune tolerance with FIX recombinant in a patient with haemophilia B with inhibitor.
Soto I; Vicente JM; Corte JR; Urgellés MF; Pinto CR
Haemophilia; 2004 Jul; 10(4):401-4. PubMed ID: 15230957
[TBL] [Abstract][Full Text] [Related]
6. Inhibitor development in haemophilia B: an orphan disease in need of attention.
DiMichele D
Br J Haematol; 2007 Aug; 138(3):305-15. PubMed ID: 17614818
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
Mathias M; Khair K; Hann I; Liesner R
Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
[TBL] [Abstract][Full Text] [Related]
8. Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units.
Ter Avest PC; Fischer K; Gouw SC; Van Dijk K; Mauser-Bunschoten EP
Haemophilia; 2010 May; 16(102):71-9. PubMed ID: 20536988
[TBL] [Abstract][Full Text] [Related]
9. ITI with high-dose FIX and combined immunosuppressive therapy in a patient with severe haemophilia B and inhibitor.
Beutel K; Hauch H; Rischewski J; Kordes U; Schneppenheim J; Schneppenheim R
Hamostaseologie; 2009 May; 29(2):155-7. PubMed ID: 19404519
[TBL] [Abstract][Full Text] [Related]
10. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.
Astermark J; Morado M; Rocino A; van den Berg HM; von Depka M; Gringeri A; Mantovani L; Garrido RP; Schiavoni M; Villar A; Windyga J;
Haemophilia; 2006 Jul; 12(4):363-71. PubMed ID: 16834735
[TBL] [Abstract][Full Text] [Related]
11. Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor.
Klarmann D; Martinez Saguer I; Funk MB; Knoefler R; von Hentig N; Heller C; Kreuz W
Haemophilia; 2008 Jan; 14(1):44-9. PubMed ID: 18081836
[TBL] [Abstract][Full Text] [Related]
12. Factor IX antibody and immune tolerance.
Warrier I
Vox Sang; 1999; 77 Suppl 1():70-1. PubMed ID: 10529693
[TBL] [Abstract][Full Text] [Related]
13. Induction of immune tolerance using rituximab in a child with severe haemophilia B with inhibitors and anaphylaxis to factor IX.
Barnes C; Davis A; Furmedge J; Egan B; Donnan L; Monagle P
Haemophilia; 2010 Sep; 16(5):840-1. PubMed ID: 20546030
[No Abstract] [Full Text] [Related]
14. Immune tolerance induction for a patient with factor IX inhibitors--a case report.
Nagel K; Laudenbach L; Rivard GE; Jardine L; Chan AK; Pai MK
Haemophilia; 2011 Mar; 17(2):315. PubMed ID: 20825499
[No Abstract] [Full Text] [Related]
15. Anaphylactoid reactions and nephrotic syndrome--a considerable risk during factor IX treatment in patients with haemophilia B and inhibitors: a report on the outcome in two brothers.
Tengborn L; Hansson S; Fasth A; Lübeck PO; Berg A; Ljung R
Haemophilia; 1998 Nov; 4(6):854-9. PubMed ID: 10028310
[TBL] [Abstract][Full Text] [Related]
16. Successful management of factor IX inhibitor-associated nephrotic syndrome in a hemophilia B patient.
Verghese P; Darrow S; Kurth MH; Reed RC; Kim Y; Kearney S
Pediatr Nephrol; 2013 May; 28(5):823-6. PubMed ID: 23381011
[TBL] [Abstract][Full Text] [Related]
17. Successful induction of immune tolerance in a patient with haemophilia B with inhibitor.
Suzuki N; Watanabe J; Kudoh T; Hori T; Hatakeyama N; Mizue N; Oda T; Tsutsumi H
Haemophilia; 2003 May; 9(3):340-2. PubMed ID: 12694528
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors in haemophilia A: current management and open issues.
Haya S; Moret A; Cid AR; Cortina V; Casaña P; Cabrera N; Aznar JA
Haemophilia; 2007 Dec; 13 Suppl 5():52-60. PubMed ID: 18078398
[TBL] [Abstract][Full Text] [Related]
19. Immune tolerance: critical issues of factor dose, purity and treatment complications.
DiMichele DM
Haemophilia; 2006 Dec; 12 Suppl 6():81-5; discussion 85-6. PubMed ID: 17123399
[TBL] [Abstract][Full Text] [Related]
20. Eradication of FIX inhibitor in haemophilia B children using low-dose immune tolerance induction with rituximab-based immunosuppressive agent(s) in China.
Li Z; Liu G; Yao W; Chen Z; Li G; Cheng X; Zhen Y; Ai D; Huang K; Sun J; Poon MC; Wu R
Haemophilia; 2022 Jul; 28(4):625-632. PubMed ID: 35503087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
